Recalibrating Intellectual Property Rights to Enhance Translational Research Collaborations

Bubela, Tania; FitzGerald, Garret A.; Gold, E. Richard

doi:10.1126/scitranslmed.3003490

Cited by 34 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One issue that remains an ongoing challenge to collaborative efforts is ownership of data; negotiation of IPR and contracts in collaborative trials can result in considerable project delays and new policies to manage licensing agreements are required [36]. As part of these discussions, consideration must be given to whether discoveries were part of the original protocol or later research projects, as well as to who has funded these projects.…”

Section: Models Of Collaboration In Translational Oncologymentioning

confidence: 99%

Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development

Stahel

Bogaerts

Ciardiello

et al. 2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

Despite intense efforts, the socioeconomic burden of cancer remains unacceptably high and treatment advances for many common cancers have been limited, suggesting a need for a new approach to drug development. One issue central to this lack of progress is the heterogeneity and genetic complexity of many tumours. This results in considerable variability in therapeutic response and requires knowledge of the molecular profile of the tumour to guide appropriate treatment selection for individual patients. While recent advances in the molecular characterisation of different cancer types have the potential to transform cancer treatment through precision medicine, such an approach presents a major economic challenge for drug development, since novel targeted agents may only be suitable for a small cohort of patients. Identifying the patients who would benefit from individual therapies and recruiting sufficient numbers of patients with particular cancer subtypes into clinical trials is challenging, and will require collaborative efforts from research groups and industry in order to accelerate progress. A number of molecular screening platforms have already been initiated across Europe, and it is hoped that these networks, along with future collaborations, will benefit not only patients but also society through cost reductions as a result of more efficient use of resources. This review discusses how current developments in translational oncology may be applied in clinical practice in the future, assesses current programmes for the molecular characterisation of cancer and describes possible collaborative approaches designed to maximise the benefits of translational science for patients with cancer.

show abstract

Section: Models Of Collaboration In Translational Oncologymentioning

confidence: 99%

Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development

Stahel

Bogaerts

Ciardiello

et al. 2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…Research in many fields, including health, has also used PPPs (7). Particularly in the context of healthcare and health-related research, many PPPs are created to make the process of R&D of drugs, vaccines, diagnostic tests, and medical devices more efficient and effective, as well as to improve patients’ access to medical innovative products (2, 4, 8, 9). …”

Section: Contextmentioning

confidence: 99%

Public–Private Partnerships in Cloud-Computing Services in the Context of Genomic Research

2017

View full text Add to dashboard Cite

Public–private partnerships (PPPs) have been increasingly used to spur and facilitate innovation in a number of fields. In healthcare, the purpose of using a PPP is commonly to develop and/or provide vaccines and drugs against communicable diseases, mainly in developing or underdeveloped countries. With the advancement of technology and of the area of genomics, these partnerships also focus on large-scale genomic research projects that aim to advance the understanding of diseases that have a genetic component and to develop personalized treatments. This new focus has created new forms of PPPs that involve information technology companies, which provide computing infrastructure and services to store, analyze, and share the massive amounts of data genomic-related projects produce. In this article, we explore models of PPPs proposed to handle, protect, and share the genomic data collected and to further develop genomic-based medical products. We also identify the reasons that make these models suitable and the challenges they have yet to overcome. To achieve this, we describe the details and complexities of MSSNG, International Cancer Genome Consortium, and 100,000 Genomes Project, the three PPPs that focus on large-scale genomic research to better understand the genetic components of autism, cancer, rare diseases, and infectious diseases with the intention to find appropriate treatments. Organized as PPP and employing cloud-computing services, the three projects have advanced quickly and are likely to be important sources of research and development for future personalized medicine. However, there still are unresolved matters relating to conflicts of interest, commercialization, and data control. Learning from the challenges encountered by past PPPs allowed us to establish that developing guidelines to adequately manage personal health information stored in clouds and ensuring the protection of data integrity and privacy would be critical steps in the development of future PPPs.

show abstract

“…However, we should not underestimate cultural barriers or the complications associated with managing intellectual property, two aspects that have historically hampered interaction between academia and industry ( 48 ). To overcome these long-standing barriers between academia and industry, we must be creative and innovative in the way we use current business models in drug discovery and development as well as the way we envisage collaborations ( 49 ).…”

Section: Academia-industry Partnerships: a Path Forwardmentioning

confidence: 99%

Oncology Drug Discovery: Planning a Turnaround

et al. 2014

View full text Add to dashboard Cite

Summary:We have made remarkable progress in our understanding of the pathophysiology of cancer. This improved understanding has resulted in increasingly effective targeted therapies that are better tolerated than conventional cytotoxic agents and even curative in some patients. Unfortunately, the success rate of drug approval has been limited, and therapeutic improvements have been marginal, with too few exceptions. In this article, we review the current approach to oncology drug discovery and development, identify areas in need of improvement, and propose strategies to improve patient outcomes. We also suggest future directions that may improve the quality of preclinical and early clinical drug evaluation, which could lead to higher approval rates of anticancer drugs. Cancer Discov;4(4);[397][398][399][400][401][402][403][404]

show abstract

Recalibrating Intellectual Property Rights to Enhance Translational Research Collaborations

Cited by 34 publications

References 28 publications

Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development

Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development

Public–Private Partnerships in Cloud-Computing Services in the Context of Genomic Research

Oncology Drug Discovery: Planning a Turnaround

Contact Info

Product

Resources

About